002082.SZ
Wanbangde Pharmaceutical Holding Group Co., Ltd. [002082.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002082.SZ Stock Summary
Top 10 Correlated Stocks
002082.SZ
In the News
002082.SZ Financial details
Company Rating
Neutral
Market Cap
2.88B
Income
-72.16M
Revenue
1.62B
Book val./share
4.26
Cash/share
0.5
Dividend
0.12
Dividend %
1.91%
Employees
1.57K
Optionable
No
Shortable
Yes
Earnings
26 Oct 2023
P/E
-53.74
Forward P/E
-
PEG
3.71
P/S
2.37
P/B
1.49
P/C
8.5
P/FCF
-13.76
Quick Ratio
1.32
Current Ratio
1.57
Debt / Equity
0.43
LT Debt / Equity
0.06
-
-
EPS (TTM)
-0.12
EPS next Y
-
EPS next Q
-
EPS this Y
-55.56%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-19.27%
Revenue last 5Y
-34.07%
Revenue Q/Q
-20.94%
EPS Q/Q
-1000%
-
-
-
-
SMA20
-
SMA50
-16.67%
SMA100
-28.57%
Inst Own
-
Inst Trans
-
ROA
-2%
ROE
-3%
ROC
-0.02%
Gross Margin
47%
Oper. Margin
-3%
Profit Margin
-4%
Payout
-165%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.7-8.64
52W High
-46.88%
52W Low
+41.67%
RSI
38
Rel Volume
0.71
Avg Volume
5.65M
Volume
3.99M
Perf Week
-12.91%
Perf Month
-14.14%
Perf Quarter
-32.65%
Perf Half Y
-40.64%
-
-
-
-
Beta
0.684
-
-
Volatility
0.24%, 0.28%
Prev Close
-0.93%
Price
4.25
Change
-4.06%
002082.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 60.23 | 66.37 | 22.6 | 3.13 | 2.91 | |
| Net income per share | 0.35 | 0.66 | 0.47 | 0.27 | 0.12 | |
| Operating cash flow per share | 0.57 | -1.04 | 0.25 | 0.04 | -0.39 | |
| Free cash flow per share | -0.27 | -2.75 | -0.67 | -0.41 | -0.66 | |
| Cash per share | 2.08 | 2.72 | 0.93 | 1.46 | 0.75 | |
| Book value per share | 6.27 | 6.88 | 4.32 | 4.21 | 4.38 | |
| Tangible book value per share | 4.79 | 5.27 | 3.52 | 3.46 | 3.64 | |
| Share holders equity per share | 6.27 | 6.88 | 4.32 | 4.21 | 4.38 | |
| Interest debt per share | 2.34 | 5.91 | 3.16 | 1.42 | 1.46 | |
| Market cap | 1.7B | 2.25B | 8.31B | 9.12B | 5.41B | |
| Enterprise value | 1.74B | 2.96B | 9.59B | 9.05B | 5.8B | |
| P/E ratio | 20.27 | 14.32 | 29.15 | 54.78 | 72.77 | |
| Price to sales ratio | 0.12 | 0.14 | 0.61 | 4.72 | 3.03 | |
| POCF ratio | 12.59 | -9.04 | 55 | 412.99 | -22.57 | |
| PFCF ratio | -26.54 | -3.44 | -20.35 | -35.77 | -13.29 | |
| P/B Ratio | 1.14 | 1.37 | 3.17 | 3.51 | 2.01 | |
| PTB ratio | 1.14 | 1.37 | 3.17 | 3.51 | 2.01 | |
| EV to sales | 0.12 | 0.19 | 0.7 | 4.69 | 3.25 | |
| Enterprise value over EBITDA | 7.24 | 7.44 | 15.46 | 14.89 | 15.47 | |
| EV to operating cash flow | 12.85 | -11.9 | 63.5 | 409.76 | -24.22 | |
| EV to free cash flow | -27.08 | -4.52 | -23.49 | -35.49 | -14.26 | |
| Earnings yield | 0.05 | 0.07 | 0.03 | 0.02 | 0.01 | |
| Free cash flow yield | -0.04 | -0.29 | -0.05 | -0.03 | -0.08 | |
| Debt to equity | 0.36 | 0.83 | 0.71 | 0.32 | 0.32 | |
| Debt to assets | 0.19 | 0.36 | 0.33 | 0.19 | 0.2 | |
| Net debt to EBITDA | 0.14 | 1.78 | 2.07 | -0.12 | 1.05 | |
| Current ratio | 1.49 | 1.81 | 1.65 | 1.92 | 1.94 | |
| Interest coverage | 5.64 | 5.56 | 9.05 | 14.4 | 8.07 | |
| Income quality | 1.08 | -1.19 | 0.52 | 0.14 | -3.22 | |
| Dividend Yield | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Payout ratio | 0.29 | 0.32 | 0.6 | 1.15 | 0.59 | |
| Sales general and administrative to revenue | 0 | 0 | 0.01 | 0.03 | 0.03 | |
| Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0.04 | 0.03 | |
| Intangibles to total assets | 0.21 | 0.17 | 0.13 | 0.14 | 0.14 | |
| Capex to operating cash flow | -1.47 | 1.63 | -3.7 | -12.55 | 0.7 | |
| Capex to revenue | -0.01 | -0.03 | -0.04 | -0.14 | -0.09 | |
| Capex to depreciation | -2.88 | -5.95 | -5.22 | -2.92 | -1.56 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | 0.02 | |
| Graham number | 7.06 | 10.11 | 6.76 | 5.06 | 3.46 | |
| ROIC | 0.06 | 0.07 | 0.1 | 0.07 | 0.06 | |
| Return on tangible assets | 0.04 | 0.05 | 0.06 | 0.04 | 0.02 | |
| Graham Net | 0.35 | -1.21 | -1.02 | 0.56 | 0.44 | |
| Working capital | 538.74M | 980.28M | 1.22B | 1.19B | 1.06B | |
| Tangible asset value | 1.14B | 1.26B | 2.14B | 2.13B | 2.24B | |
| Net current asset value | 511.77M | 300.48M | 277.76M | 842.13M | 804.29M | |
| Invested capital | 0.36 | 0.83 | 0.71 | 0.32 | 0.32 | |
| Average receivables | 555.26M | 705.39M | 1.2B | 1.42B | 1.34B | |
| Average payables | 263.71M | 302.03M | 288.47M | 305.06M | 242.85M | |
| Average inventory | 475.56M | 605.83M | 770.04M | 556.15M | 272.28M | |
| Days sales outstanding | 15.27 | 18.74 | 42.56 | 236.72 | 290.55 | |
| Days payables outstanding | 10.11 | 5.36 | 10.51 | 94.61 | 99.59 | |
| Days of inventory on hand | 13.81 | 16.68 | 25.15 | 97.17 | 121.98 | |
| Receivables turnover | 23.9 | 19.48 | 8.58 | 1.54 | 1.26 | |
| Payables turnover | 36.09 | 68.16 | 34.72 | 3.86 | 3.67 | |
| Inventory turnover | 26.44 | 21.89 | 14.51 | 3.76 | 2.99 | |
| ROE | 0.06 | 0.1 | 0.11 | 0.06 | 0.03 | |
| Capex per share | -0.84 | -1.71 | -0.92 | -0.45 | -0.27 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.74 | 0.98 | 0.63 | 0.58 | 0.46 | |
| Net income per share | 0.15 | -0.11 | 0.04 | 0.01 | -0.06 | |
| Operating cash flow per share | 0.15 | -0.11 | 0.04 | -0.1 | 0.01 | |
| Free cash flow per share | -0.05 | -0.13 | -0.02 | -0.18 | -0.13 | |
| Cash per share | 0.88 | 0.75 | 0.72 | 0.48 | 0.5 | |
| Book value per share | 4.46 | 4.38 | 4.42 | 4.33 | 4.26 | |
| Tangible book value per share | 3.63 | 3.64 | 3.68 | 3.58 | 3.5 | |
| Share holders equity per share | 4.46 | 4.38 | 4.42 | 4.33 | 4.26 | |
| Interest debt per share | 1.4 | 1.43 | 1.59 | 1.65 | 1.83 | |
| Market cap | 5.32B | 5.41B | 5.17B | 4.34B | 4.28B | |
| Enterprise value | 5.64B | 5.8B | 5.7B | 5.04B | 5.07B | |
| P/E ratio | 14.73 | -20.74 | 47.28 | 254.97 | -27.77 | |
| Price to sales ratio | 11.75 | 8.97 | 13.42 | 12.27 | 15.33 | |
| POCF ratio | 58.94 | -82.95 | 189.1 | -69.11 | 1.11K | |
| PFCF ratio | -176.7 | -66.75 | -546.36 | -38.93 | -55.46 | |
| P/B Ratio | 1.94 | 2.01 | 1.91 | 1.64 | 1.64 | |
| PTB ratio | 1.94 | 2.01 | 1.91 | 1.64 | 1.64 | |
| EV to sales | 12.46 | 9.63 | 14.8 | 14.26 | 18.16 | |
| Enterprise value over EBITDA | 42.12 | 146.05 | 147.19 | 1.6K | -344.46 | |
| EV to operating cash flow | 62.51 | -89.02 | 208.58 | -80.26 | 1.32K | |
| EV to free cash flow | -187.42 | -71.63 | -602.63 | -45.22 | -65.7 | |
| Earnings yield | 0.02 | -0.01 | 0.01 | 0 | -0.01 | |
| Free cash flow yield | -0.01 | -0.01 | 0 | -0.03 | -0.02 | |
| Debt to equity | 0.32 | 0.32 | 0.36 | 0.38 | 0.43 | |
| Debt to assets | 0.21 | 0.2 | 0.22 | 0.23 | 0.25 | |
| Net debt to EBITDA | 2.41 | 9.95 | 13.74 | 222.78 | -53.68 | |
| Current ratio | 2.1 | 1.94 | 1.77 | 1.63 | 1.57 | |
| Interest coverage | -21.28 | -1.97 | -7.88 | 0.31 | -3.24 | |
| Income quality | 1 | 1 | 1 | -14.76 | -0.1 | |
| Dividend Yield | 0 | 0 | 0 | 0.02 | 0 | |
| Payout ratio | 0.1 | -0.22 | 0.35 | 19.38 | -0.32 | |
| Sales general and administrative to revenue | 0.3 | -0.17 | 0.14 | -0.07 | 0.35 | |
| Research and developement to revenue | 0.03 | 0.02 | 0.04 | 0.04 | 0.04 | |
| Intangibles to total assets | 0.16 | 0.14 | 0.13 | 0.13 | 0.13 | |
| Capex to operating cash flow | -1.33 | 0.24 | -1.35 | 0.77 | -21.1 | |
| Capex to revenue | -0.27 | -0.03 | -0.1 | -0.14 | -0.29 | |
| Capex to depreciation | -4.65 | -0.61 | 0 | -1.61 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.84 | 3.24 | 2.1 | 0.82 | 2.46 | |
| ROIC | 0.04 | -0.01 | 0.01 | 0 | -0.01 | |
| Return on tangible assets | 0.03 | -0.02 | 0.01 | 0 | -0.01 | |
| Graham Net | 0.59 | 0.44 | 0.32 | -0.01 | -0.08 | |
| Working capital | 1.12B | 1.06B | 1.03B | 841.64M | 786.23M | |
| Tangible asset value | 2.23B | 2.24B | 2.26B | 2.19B | 2.14B | |
| Net current asset value | 846.01M | 804.29M | 772.82M | 581.18M | 516.81M | |
| Invested capital | 0.32 | 0.32 | 0.36 | 0.38 | 0.43 | |
| Average receivables | 1.23B | 1.36B | 1.52B | 1.58B | 1.53B | |
| Average payables | 161.15M | 197.45M | 263.13M | 299.86M | 285.53M | |
| Average inventory | 279.08M | 282.74M | 280.64M | 301.56M | 316.47M | |
| Days sales outstanding | 257.14 | 212.32 | 379.6 | 388.89 | 491.21 | |
| Days payables outstanding | 99.29 | 70.4 | 121.63 | 121.08 | 190.01 | |
| Days of inventory on hand | 171.22 | 86.23 | 114.64 | 129.18 | 219.63 | |
| Receivables turnover | 0.35 | 0.42 | 0.24 | 0.23 | 0.18 | |
| Payables turnover | 0.91 | 1.28 | 0.74 | 0.74 | 0.47 | |
| Inventory turnover | 0.53 | 1.04 | 0.79 | 0.7 | 0.41 | |
| ROE | 0.03 | -0.02 | 0.01 | 0 | -0.01 | |
| Capex per share | -0.2 | -0.03 | -0.06 | -0.08 | -0.13 |
002082.SZ Frequently Asked Questions
What is Wanbangde Pharmaceutical Holding Group Co., Ltd. stock symbol ?
Wanbangde Pharmaceutical Holding Group Co., Ltd. is a CN stock and trading under the symbol 002082.SZ
What is Wanbangde Pharmaceutical Holding Group Co., Ltd. stock quote today ?
Wanbangde Pharmaceutical Holding Group Co., Ltd. stock price is $4.25 today.
Is Wanbangde Pharmaceutical Holding Group Co., Ltd. stock public?
Yes, Wanbangde Pharmaceutical Holding Group Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 5.65M
- Market Capitalization 2.88B
- Employee 1.57K
- CEO Mr. Shouming Zhao
- Headquarters Taizhou,CN
- IPO Date 2006-11-20
-
Website
https://www.wepon.com.cn 
Wanbangde Pharmaceutical Holding Group Co., Ltd. engages in the research, development, production, and sale of Chinese medicines, APIs, and preparations. It also develops medical devices, including orthopaedic implant devices, medical equipment, and protective equipment, as well as disposable bacteria medical polymer consumables; and provides hospital engineering services. The company was formerly known as Wanbangde New Building Materials Co., Ltd. and changed its name to Wanbangde Pharmaceutical Holding Group Co., Ltd. in April 2020. Wanbangde Pharmaceutical Holding Group Co., Ltd. was founded in 1985 and is based in Taizhou, China.
